For middle-aged or older adults with symptomatic early-to-moderate hip OA who wish to defer or avoid joint replacement, intra-articular cell therapy offers a tissue-preserving option with modest risk. For young patients with severe OA from prior trauma, the high cost and uncertain long-term durability must be weighed against eventual surgical replacement. For asymptomatic radiographic OA, treatment is not justified.
Hip osteoarthritis (OA) develops when protective cartilage lining the femoral head and acetabulum undergoes progressive degradation—triggered by mechanical wear, inflammation, prior injury, or metabolic dysfunction—exposing the underlying bone. Cartilage lesions enlarge, bone spurs form, and synovial fluid (joint lubricant) becomes inflamed. Pain, stiffness, and loss of range of motion ensue, eventually limiting walking and activities of daily living. Cell therapy in hip OA leverages placental MSCs, engineered chondrocytes, and exosomes to deliver anti-inflammatory and cartilage-regenerative signals directly into the joint. Intra-articular injection (into the joint space) positions cells to interact with damaged cartilage surfaces, synovial tissue, and local immune cells, potentially slowing degeneration or promoting cartilage matrix repair.
Являюсь ли я кандидатом? → · Hip Osteoarthritis: full overview → · Стоимость Остеоартрит тазобедренного сустава → · Cost →
Медицинское рецензирование редакторской командой StemCellAtlas с Dr Tymur Lukyanenko (Orthopaedic Traumatologist · 20+ yrs clinical, 15+ yrs cell therapy) клиники-партнёра Stem Plus (София) в соответствии с руководствами ISSCR, FDA и EMA. Educational information, not medical advice; figures indicative.
GMP-сертифицированная регенеративная медицина в сердце ЕС — от €3 000–8 000, доля от цен США или Германии. Индивидуальные протоколы для пациентов из 50+ стран.
Бесплатная оценка врача